Kiniksa Pharmaceuticals International (KNSA) 2024 Wells Fargo Healthcare Conference summary

Commercial performance and market evolution

• ARCALYST, the first and only FDA-approved therapy for recurrent pericarditis, launched in April 2021 and has shown steady growth in net revenue, patient numbers, and prescriber base each quarter.

• The drug targets a 14,000-patient population with two or more recurrences, achieving 11% market penetration by end of Q2, with additional upside in a broader 40,000-patient label.

• Over 2,300 prescribers have adopted ARCALYST, with a growing number of repeat prescribers and increasing early treatment in first recurrence cases.

• Education efforts focus on improving diagnosis accuracy and reducing misdiagnosis, as patients average 2.7 misdiagnoses before correct identification.

• Cardiologists account for 70% of prescriptions, with rheumatologists also involved, and outreach is agnostic to practice setting.

Real-world data and treatment paradigm shift

• The RESONANCE registry, enrolling up to 500 patients, shows a shift from steroid-based management to IL-1 inhibition, with ARCALYST now used in about two-thirds of expert-managed cases.

• Prior to ARCALYST, 80% of colchicine-failing patients received corticosteroids; now, steroid use is declining as ARCALYST adoption rises.

• Registry and trial data indicate a paradigm shift to a steroid-sparing approach, with ARCALYST enabling earlier and more sustained disease control.

Growth drivers and future outlook

• Key growth areas include expanding physician education, improving patient identification, and supporting the establishment of specialist centers.

• The disease is chronic, with a median duration of three years; 45% of patients who stop ARCALYST restart therapy, reflecting the need for long-term management.

• Average treatment duration has increased to 26 months, and 15-20% of early adopters remain on continuous therapy.

• Revenue guidance for 2024 was raised to $405–$415 million, reflecting these dynamics.